Using drugs that gently reduce heart calcium stores to prevent calcium-driven arrhythmias
Partial and Controlled Depletion of SR Calcium by RyR Agonists Prevents Calcium-dependent Arrhythmias
This project looks at whether tiny doses of drugs that lower calcium inside heart cells can stop dangerous, calcium-driven irregular heartbeats in people with conditions like CPVT and related rhythm problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11252778 on NIH RePORTER |
What this research studies
From a patient point of view, researchers are testing a surprising approach: giving very small amounts of drugs that briefly open calcium release channels so the heart's calcium stores drop just enough to prevent harmful calcium leaks that trigger arrhythmias. The team will work with isolated heart cells and animal models to measure electrical activity, calcium signals, and how often abnormal heartbeats occur with and without the treatment. They will search for doses and delivery methods that stop abnormal rhythms without weakening the heart's pumping action. These are preclinical lab studies aimed at informing possible future human trials.
Who could benefit from this research
Good fit: People with catecholaminergic polymorphic ventricular tachycardia (CPVT) or other arrhythmias linked to calcium overload could be the most likely candidates for future trials of this approach.
Not a fit: Patients whose arrhythmias are caused primarily by structural heart disease, scar-related reentry, or electrical problems not related to calcium handling are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could lead to new treatments that prevent life-threatening calcium-driven arrhythmias while avoiding the side effects of current blockers.
How similar studies have performed: Some RyR-targeting drugs and related strategies have shown promise in lab models and select CPVT cases, but using controlled RyR agonists to lower calcium stores is a novel and mostly untested strategy in humans.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Valdivia, Hector H — University of Wisconsin-Madison
- Study coordinator: Valdivia, Hector H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.